Thanks! I knew about that stuff but I didn't know how to boot the 2.9BSD_rl02_1145 image. After you reminded me that the device name was prepended to the kernel name I suceeded:
$ pdp11
PDP-11 simulator V2.8-5
sim> set cpu 18b
sim> set cpu 2m
sim> at rl0 2.9BSD_rl02_1145
sim> b rl
:boot
45Boot
: rl(0,0,0)rl2unix
rl2unix not found
: rl(0,0,0)stand/ls
stand not found
: rl(0,0,0)rlunix
Berkeley UNIX (Rev. 2.9.1) Sun Nov 20 14:55:50 PST 1983
mem = 135872
CONFIGURE SYSTEM:
xp 0 csr 176700 vector 254 attached
rk 0 csr 177400 vector 220 attached
hk ? csr 177440 vector 210 skipped: No CSR
rl 0 csr 174400 vector 160 attached
rp ? csr 176700 vector 254 interrupt vector already in use
ht 0 csr 172440 vector 224 skipped: No CSR
tm 0 csr 172520 vector 224 attached
ts 0 csr 172520 vector 224 interrupt vector already in use
dh ? csr 160020 vector 370 skipped: No CSR
dm ? csr 170500 vector 360 skipped: No autoconfig routines
dz ? csr 160110 vector 320 skipped: No CSR
dz ? csr 160110 vector 320 skipped: No CSR
dn 0 csr 175200 vector 300 skipped: No autoconfig routines
vp ? csr 177500 vector 174 skipped: No autoconfig routines
lp 0 csr 177514 vector 200 attached
Erase=^?, kill=^U, intr=^C
#
I had completely forgotten about Northern Lights until I read about their GeoSearch feature. I gave it a shot and loved the results. I know about lasso (or whatever) but didn't like it. Is there something else out there as good as Northern Lights Geosearch?
AccessX is built into the XKEYBOARD extension of the X11R6.1 and later versions. It's just not very visible or well known. If you have run xf86cfg then you have seen the accessx client.
In case motor skills handcaps make using a mouse too difficult:
MouseKeys allows the numeric keypad to be used instead.
SlowKeys prevents accidental input.
BounceKeys prevents double keyboard bounces.
StickyKeys makes the Shift key like a one-shot CAPSlock in case you can't hold down two keys at once.
AccessX is a set of features within the XKEYBOARD extension of the X Window System designed to make X more accessible to users with disabilities. XKEYBOARD is present in X11R6.1 and later. AccessX features are typically unknown, given that in many implementations no interface is provided to utilize their functionality. Sun, IBM, and SGI all provide a utility called accessx that enables the user to get, set, and store in a configuration file many of the AccessX features. In general, though, there has not been a freeware utility to perform this task until now.
According to the Washington Post the xbox failed to sell out completely like other consoles have. Seems many people were waiting for the GameCube instead.
The U.S. Government did all the R&D for ddI. They could not market it so they used some selection process to license it to Bristol Meyers Squibb (BMS) for ten years. BMS turns around and goes for the jugular when Thailand tries to klone ddI. Eventually this happened:
-----
* Date: Mon, 17 Jan 2000 19:47:24 -0500 (EST)
THAILAND WILL PRODUCE GENERIC DDI POWDER
The Thai Ministry of Public Health today announced that it will not apply compulsory license but that it will let the Government Pharmaceutical Organization (GPO) produce the powder of ddI. About 100 activists had gathered outside the Ministry of Public Health to hear the decision of the Public Health Minister.
ddI powder is not patent protected in Thailand. One sachet will cost $0.7 (equivalent to 150 mg); daily cost will therefore be $ 1.4 compared to currently about $ 3.7 No generic tablets will be available because of the patent.
The problem with ddI is the expensive raw material because there is only one relatively small supplier in Canada. Raw material from a Japanese producer is only 55% of the cost but this is the BMS supplier and BMS has prevented the company from selling to other customers. If BMS would be interested to actually do something for people they could offer ddI at a daily cost of probably less than $ 1.0!
No discount for the BMS product has been announced so far.
There are many open questions:
As reason for not applying compulsory license the Ministry of Public Health quoted fear for a BMS law suit and lacking support from the Dept of Intellectual Property. The Dept. of Intellectual Property said that they were "worried" to use compulsory license but refused to name reasons. Several activists questioned why compulsory license is in the law if it can not be used.
The Public Health Minister was asked why ddI powder was not produced already two years ago; he replied that he was not yet Health Minister at that time.
The NGO network had demanded compulsory license for ddI since last year and had also demanded the production of ddI powder as an interim solution. NGO representatives will meet with the US ambassador to Thailand tomorrow, Tuesday to hand over a letter to President Clinton asking for a statement that the US government will not interfere if Thailand uses compulsory license for ddI.
Tido von Schoen-Angerer, MD
MSF Thailand
msfdrugs@asianet.co.th-th-th-end
(remove "-th-th-end" to reply)
Cipla, which shot into international prominence in February by offering to supply combination antiretroviral therapy for less than $1 a day, said in a statement that a month's supply of the new pill, Triomune, would cost patients $38.21.
The sad fact is that this is an export price. People in India are expected to pay more than this for the drug.
BOMBAY (Reuters Health) Aug 06 - Indian drugmaker Cipla Ltd said on Monday that it has launched the first three-in-one tablet to treat HIV infection that contains the antiretroviral drugs stavudine, lamivudine and nevirapine.
Cipla, which shot into international prominence in February by offering to supply combination antiretroviral therapy for less than $1 a day, said in a statement that a month's supply of the new pill, Triomune, would cost patients $38.21.
The company statement said the price represented a five- to six-fold reduction in the monthly cost of therapy. The new product is the first to combine the three antiretroviral drugs in one tablet, which has not been available because the patents for these drugs are controlled by different companies.
Britain's GlaxoSmithKline holds the patent on lamivudine, Germany's Boehringer Ingelheim has the patent on nevirapine and US drug giant Bristol-Myers Squibb holds the patent on stavudine.
Cipla is permitted by Indian patent law to make drugs that are patented by other companies internationally because the law protects only the processes by which drugs are made, and not the drugs themselves. This means Indian companies can make drugs under patent in the West, provided they use a process that is different from the original.
In February, the company offered to supply the three drugs to the international charity Medecins Sans Frontieres for $350 per patient per year, a thirtieth of the US price.
ZURICH (Reuters Health) Aug 23 - Swiss healthcare group Roche Holding AG sought to head off a fresh debate over the pricing of AIDS drugs in the developing world by insisting on Thursday that it was close to a cut-price deal with Brazil.
Stunned by Brazil's threat to break a patent on Roche drug nelfinavir (Viracept), and to make the medicine in a state factory at a fraction of the cost, Roche said an accord was within reach to cut its discounted price for Viracept even more in 2002.
"We were extremely surprised to hear the news...because we have been in a long-standing relationship with the Brazilian government, which has been particularly committed to active programmes to handle AIDS in Brazil," a Roche spokesman said. Roche now sells Viracept, whose patent is held by US firm Pfizer Inc., at less than half the US wholesale price in Brazil and has offered a steeper discount in 2002, he added.
"We are very close to reaching an agreement which is based upon a further, additional discount," spokesman Daniel Piller said. He said Basel-based Roche also intends to start manufacturing Viracept tablets in Brazil next year and to continue to provide Viracept syrup free of charge to Brazilian children with AIDS.
Brazil's health minister, Jose Serra, said on Wednesday he had started the process of issuing a compulsory license to make Viracept at a Brazilian factory after failing to obtain sufficient price concessions from Roche. Under Brazilian law the government can issue a compulsory license to make a patented drug when a "national emergency" is invoked.
If the plan proceeds, it may be the first patent violation of an AIDS drug in the world and make the medicine available at lower prices in Brazil early next year.
The Brazilian dispute could eventually spread to include US officials, who filed a complaint against Brazil's patent law with the World Trade Organisation earlier this year, then withdrew it under pressure from world leaders and health organisations who praise Brazil's aggressive response to AIDS.
"We understand that any decision to declare a compulsory license requires the communication of this decision to the US Trade Representative. This was something which was agreed between the Brazilian and US governments in July 2001 and that is also a reason why we were surprised," Piller said.
Slashdot Mirror
Thanks! I knew about that stuff but I didn't know how to boot the 2.9BSD_rl02_1145 image. After you reminded me that the device name was prepended to the kernel name I suceeded:
$ pdp11
PDP-11 simulator V2.8-5
sim> set cpu 18b
sim> set cpu 2m
sim> at rl0 2.9BSD_rl02_1145
sim> b rl
:boot
45Boot
: rl(0,0,0)rl2unix
rl2unix not found
: rl(0,0,0)stand/ls
stand not found
: rl(0,0,0)rlunix
Berkeley UNIX (Rev. 2.9.1) Sun Nov 20 14:55:50 PST 1983
mem = 135872
CONFIGURE SYSTEM:
xp 0 csr 176700 vector 254 attached
rk 0 csr 177400 vector 220 attached
hk ? csr 177440 vector 210 skipped: No CSR
rl 0 csr 174400 vector 160 attached
rp ? csr 176700 vector 254 interrupt vector already in use
ht 0 csr 172440 vector 224 skipped: No CSR
tm 0 csr 172520 vector 224 attached
ts 0 csr 172520 vector 224 interrupt vector already in use
dh ? csr 160020 vector 370 skipped: No CSR
dm ? csr 170500 vector 360 skipped: No autoconfig routines
dz ? csr 160110 vector 320 skipped: No CSR
dz ? csr 160110 vector 320 skipped: No CSR
dn 0 csr 175200 vector 300 skipped: No autoconfig routines
vp ? csr 177500 vector 174 skipped: No autoconfig routines
lp 0 csr 177514 vector 200 attached
Erase=^?, kill=^U, intr=^C
#
I had completely forgotten about Northern Lights until I read about their GeoSearch feature. I gave it a shot and loved the results. I know about lasso (or whatever) but didn't like it. Is there something else out there as good as Northern Lights Geosearch?
Does not affect things like
telnet locis.loc.gov
In case motor skills handcaps make using a mouse too difficult:
Here's the location of the client software and documentation:
http://cmos-eng.rehab.uiuc.edu/accessx/
http://cmos-eng.rehab.uiuc.edu/accessx/
I could just see it now: "This is the part that initialize the boot sector and this is the part that keeps you from pirating the OS"
According to the Washington Post the xbox failed to sell out completely like other consoles have. Seems many people were waiting for the GameCube instead.
from Oct 1, 2001
Red cross doesn't care if you're gay or not
guess again
The U.S. Government did all the R&D for ddI. They could not market it so they used some selection process to license it to Bristol Meyers Squibb (BMS) for ten years. BMS turns around and goes for the jugular when Thailand tries to klone ddI. Eventually this happened:
-----
* Date: Mon, 17 Jan 2000 19:47:24 -0500 (EST)
THAILAND WILL PRODUCE GENERIC DDI POWDER
The Thai Ministry of Public Health today announced that it will not apply compulsory license but that it will let the Government Pharmaceutical Organization (GPO) produce the powder of ddI. About 100 activists had gathered outside the Ministry of Public Health to hear the decision of the Public Health Minister.
ddI powder is not patent protected in Thailand. One sachet will cost $0.7 (equivalent to 150 mg); daily cost will therefore be $ 1.4 compared to currently about $ 3.7 No generic tablets will be available because of the patent.
The problem with ddI is the expensive raw material because there is only one relatively small supplier in Canada. Raw material from a Japanese producer is only 55% of the cost but this is the BMS supplier and BMS has prevented the company from selling to other customers. If BMS would be interested to actually do something for people they could offer ddI at a daily cost of probably less than $ 1.0!
No discount for the BMS product has been announced so far.
There are many open questions:
As reason for not applying compulsory license the Ministry of Public Health quoted fear for a BMS law suit and lacking support from the Dept of Intellectual Property. The Dept. of Intellectual Property said that they were "worried" to use compulsory license but refused to name reasons. Several activists questioned why compulsory license is in the law if it can not be used.
The Public Health Minister was asked why ddI powder was not produced already two years ago; he replied that he was not yet Health Minister at that time.
The NGO network had demanded compulsory license for ddI since last year and had also demanded the production of ddI powder as an interim solution. NGO representatives will meet with the US ambassador to Thailand tomorrow, Tuesday to hand over a letter to President Clinton asking for a statement that the US government will not interfere if Thailand uses compulsory license for ddI.
Tido von Schoen-Angerer, MD
MSF Thailand
msfdrugs@asianet.co.th-th-th-end
(remove "-th-th-end" to reply)
Cipla, which shot into international prominence in February by offering to supply combination antiretroviral therapy for less than $1 a day, said in a statement that a month's supply of the new pill, Triomune, would cost patients $38.21.
The sad fact is that this is an export price. People in India are expected to pay more than this for the drug.
BOMBAY (Reuters Health) Aug 06 - Indian drugmaker Cipla Ltd said on Monday that it has launched the first three-in-one tablet to treat HIV infection that contains the antiretroviral drugs stavudine, lamivudine and nevirapine.
Cipla, which shot into international prominence in February by offering to supply combination antiretroviral therapy for less than $1 a day, said in a statement that a month's supply of the new pill, Triomune, would cost patients $38.21.
The company statement said the price represented a five- to six-fold reduction in the monthly cost of therapy. The new product is the first to combine the three antiretroviral drugs in one tablet, which has not been available because the patents for these drugs are controlled by different companies.
Britain's GlaxoSmithKline holds the patent on lamivudine, Germany's Boehringer Ingelheim has the patent on nevirapine and US drug giant Bristol-Myers Squibb holds the patent on stavudine.
Cipla is permitted by Indian patent law to make drugs that are patented by other companies internationally because the law protects only the processes by which drugs are made, and not the drugs themselves. This means Indian companies can make drugs under patent in the West, provided they use a process that is different from the original.
In February, the company offered to supply the three drugs to the international charity Medecins Sans Frontieres for $350 per patient per year, a thirtieth of the US price.
Stunned by Brazil's threat to break a patent on Roche drug nelfinavir (Viracept), and to make the medicine in a state factory at a fraction of the cost, Roche said an accord was within reach to cut its discounted price for Viracept even more in 2002.
"We were extremely surprised to hear the news...because we have been in a long-standing relationship with the Brazilian government, which has been particularly committed to active programmes to handle AIDS in Brazil," a Roche spokesman said. Roche now sells Viracept, whose patent is held by US firm Pfizer Inc., at less than half the US wholesale price in Brazil and has offered a steeper discount in 2002, he added.
"We are very close to reaching an agreement which is based upon a further, additional discount," spokesman Daniel Piller said. He said Basel-based Roche also intends to start manufacturing Viracept tablets in Brazil next year and to continue to provide Viracept syrup free of charge to Brazilian children with AIDS.
Brazil's health minister, Jose Serra, said on Wednesday he had started the process of issuing a compulsory license to make Viracept at a Brazilian factory after failing to obtain sufficient price concessions from Roche. Under Brazilian law the government can issue a compulsory license to make a patented drug when a "national emergency" is invoked.
If the plan proceeds, it may be the first patent violation of an AIDS drug in the world and make the medicine available at lower prices in Brazil early next year.
The Brazilian dispute could eventually spread to include US officials, who filed a complaint against Brazil's patent law with the World Trade Organisation earlier this year, then withdrew it under pressure from world leaders and health organisations who praise Brazil's aggressive response to AIDS.
"We understand that any decision to declare a compulsory license requires the communication of this decision to the US Trade Representative. This was something which was agreed between the Brazilian and US governments in July 2001 and that is also a reason why we were surprised," Piller said.